Hemispherx Biopharma Stock Price, News & Analysis (NYSEAMERICAN:HEB)

$0.31 0.00 (0.00 %)
(As of 12/15/2017 10:59 AM ET)
Previous Close$0.31
Today's Range$0.31 - $0.32
52-Week Range$0.30 - $0.93
Volume567,400 shs
Average Volume309,334 shs
Market Capitalization$11.55 million
P/E RatioN/A
Dividend YieldN/A

About Hemispherx Biopharma (NYSEAMERICAN:HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Receive HEB News and Ratings via Email

Sign-up to receive the latest news and ratings for HEB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($0.28)
Net IncomeN/A
Net Margins-1,391.11%
Return on Equity-49.30%
Return on Assets-32.57%


Outstanding Shares31,870,000

Hemispherx Biopharma (NYSEAMERICAN:HEB) Frequently Asked Questions

What is Hemispherx Biopharma's stock symbol?

Hemispherx Biopharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."

How were Hemispherx Biopharma's earnings last quarter?

Hemispherx Biopharma, Inc. (NYSEAMERICAN:HEB) issued its quarterly earnings data on Wednesday, November, 15th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $0.09 million for the quarter. Hemispherx Biopharma had a negative net margin of 1,391.11% and a negative return on equity of 49.30%. View Hemispherx Biopharma's Earnings History.

Are investors shorting Hemispherx Biopharma?

Hemispherx Biopharma saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,207,594 shares, an increase of 7.0% from the November 15th total of 1,129,042 shares. Based on an average daily volume of 325,854 shares, the days-to-cover ratio is presently 3.7 days. Currently, 4.0% of the company's stock are sold short.

Who are some of Hemispherx Biopharma's key competitors?

Who are Hemispherx Biopharma's key executives?

Hemispherx Biopharma's management team includes the folowing people:

  • William M. Mitchell, Chairman of the Board (Age 81)
  • Thomas K. Equels Esq., Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel (Age 64)
  • Adam Pascale CPA, Chief Financial Officer (Age 68)
  • Wayne Steven Springate, Senior Vice President - Operations (Age 45)
  • David R. Strayer M.D., Chief Scientific & Medical Officer (Age 70)
  • Peter W. Rodino III, Esq., Executive Director - Governmental Relations, General Counsel (Age 65)
  • Stewart L. Appelrouth, Director

How do I buy Hemispherx Biopharma stock?

Shares of Hemispherx Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hemispherx Biopharma's stock price today?

One share of Hemispherx Biopharma stock can currently be purchased for approximately $0.31.

How big of a company is Hemispherx Biopharma?

Hemispherx Biopharma has a market capitalization of $11.55 million.

How can I contact Hemispherx Biopharma?

Hemispherx Biopharma's mailing address is One Penn Center 1617 Jfk Blvd, Suite #500, PHILADELPHIA, PA 19103, United States. The specialty pharmaceutical company can be reached via phone at +1-215-9880080.

MarketBeat Community Rating for Hemispherx Biopharma (HEB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Hemispherx Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hemispherx Biopharma (NYSEAMERICAN:HEB) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Hemispherx Biopharma (NYSEAMERICAN:HEB) Earnings History and Estimates Chart

Earnings by Quarter for Hemispherx Biopharma (NYSEAMERICAN:HEB)

Hemispherx Biopharma (NYSEAMERICAN HEB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017Q3 2017($0.04)$0.09 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.08)$0.21 millionViewN/AView Earnings Details
11/14/2016Q3 16($0.30)$0.02 millionViewN/AView Earnings Details
8/15/2016Q216($0.01)$0.02 millionViewN/AView Earnings Details
5/16/2016Q116($0.01)$40.99 million$0.04 millionViewN/AView Earnings Details
8/13/2015Q2($0.02)$0.05 millionViewN/AView Earnings Details
5/13/2015Q1 15($0.02)$0.04 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.03)ViewN/AView Earnings Details
11/5/2012Q312($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Hemispherx Biopharma (NYSEAMERICAN:HEB) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Hemispherx Biopharma (NYSEAMERICAN:HEB)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Hemispherx Biopharma (NYSEAMERICAN HEB) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Hemispherx Biopharma (NYSEAMERICAN:HEB)

Hemispherx Biopharma (NYSEAMERICAN HEB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2017Adam PascaleCFOBuy15,873$0.63$9,999.99View SEC Filing  
5/2/2017David R StrayerInsiderBuy7,937$0.63$5,000.31View SEC Filing  
4/27/2017Thomas K EquelsCEOBuy72,464$0.69$50,000.16View SEC Filing  
4/11/2017Thomas K EquelsCEOBuy200,000$0.50$100,000.00View SEC Filing  
2/16/2017Adam PascaleCFOBuy6,981$0.46$3,211.26View SEC Filing  
2/16/2017David R StrayerInsiderBuy9,892$0.46$4,550.32View SEC Filing  
2/16/2017Wayne S SpringateSVPBuy8,014$0.46$3,686.44View SEC Filing  
12/22/2016Thomas K EquelsCEOBuy68,493$0.73$49,999.89View SEC Filing  
11/1/2016Thomas K EquelsCEOBuy10,000$1.00$10,000.00View SEC Filing  
7/8/2016Thomas K EquelsCEOBuy48,000$0.12$5,760.00View SEC Filing  
7/1/2016Thomas K EquelsCEOBuy171,000$0.12$20,520.00View SEC Filing  
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.00View SEC Filing  
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.00View SEC Filing  
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.00View SEC Filing  
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Hemispherx Biopharma (NYSEAMERICAN HEB) News Headlines

Short Interest in Hemispherx Biopharma, Inc. (HEB) Increases By 7.0%Short Interest in Hemispherx Biopharma, Inc. (HEB) Increases By 7.0%
www.americanbankingnews.com - December 11 at 7:58 PM
ETFs with exposure to Hemispherx Biopharma, Inc. : December 5, 2017ETFs with exposure to Hemispherx Biopharma, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 1:02 PM
Hemispherx Biopharma, Inc. (HEB) Short Interest Up 4.2% in NovemberHemispherx Biopharma, Inc. (HEB) Short Interest Up 4.2% in November
www.americanbankingnews.com - November 28 at 1:04 AM
Hemispherx BioPharma, Inc (HEB) Releases  Earnings ResultsHemispherx BioPharma, Inc (HEB) Releases Earnings Results
www.americanbankingnews.com - November 16 at 6:44 PM
Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV - GlobeNewswire (press release)Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV - GlobeNewswire (press release)
globenewswire.com - November 16 at 4:02 PM
Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TVHemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV
feeds.benzinga.com - November 15 at 9:57 AM
HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?
finance.yahoo.com - November 14 at 3:51 PM

SEC Filings

Hemispherx Biopharma (NYSEAMERICAN:HEB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Hemispherx Biopharma (NYSEAMERICAN:HEB) Income Statement, Balance Sheet and Cash Flow Statement


Hemispherx Biopharma (NYSEAMERICAN HEB) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.